Abstract
More than 90% cancer deaths are caused by cancer metastasis. As cancer metastasis is the main cause of human deaths, we shall pay more attentions on it. Currently, treatment and chemotherapy are focused on primary tumors rather than metastatic processes. Antimetastatic drugs are often used as assistant therapy. So cancer patients’ survivals have been improved very little. To change this mindset, we highlight this problem by giving new perspectives and try to improve the outcome of chemotherapy of cancer patients from different possible ways. Human cancer metastasis is a long-evolving, multi-steps process that can only be treated or controlled by drugs or immuno-modulators by now. Human neoplasm metastasis, at least a month-long course, encompasses several different substages and affects or being affected by numerous genes and molecules. We have found that each drug or immuno-modulator might act differently within the various stages of a metastatic course. We, therefore, suggest that future antimetastatic therapy should be strategically optimized according to characteristics of metastatic processes in order to reach maximum therapeutic benefits. In this view, we propose, address and support this issue by using past literature evidence, our experimentations and existing biological, anatomical and pathologic characteristics.
Highlights
Present Clinical Antimetastatic TherapyPresent antimetastatic treatments are overwhelmed with researches and applications of antivascular (angiogenesis) and matrix metalloproteinase (MMPs) inhibitors and more than 500 relatedagents of different chemical formulae have been literally reported
More than 90% cancer deaths are caused by cancer metastasis
Present antimetastatic treatments are overwhelmed with researches and applications of antivascular and matrix metalloproteinase (MMPs) inhibitors and more than 500 relatedagents of different chemical formulae have been literally reported
Summary
Present antimetastatic treatments are overwhelmed with researches and applications of antivascular (angiogenesis) and matrix metalloproteinase (MMPs) inhibitors and more than 500 relatedagents of different chemical formulae have been literally reported. All FDA licensed or internationally available antimetastatic drugs are generally consisted with these two types [2,3,4,5] These drugs are far from satisfactory in clinics for the reasons of indiscriminative molecular inhibitions and generally low survival benefits for patients. Finding important drugs targeting to neoplasm metastases is essential and indispensable [1, 11,12,13]. It needs changing our focus from targeting vascularity and MMPs into more metastatic-relating molecules. How to optimistically use drugs in antimetastatic treatments remains to be a great challenge
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
